skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

About Aidan

UK

+23 year(s) experience

Aidan_Fry_Pharma_Intelligence
As the co-founder of Generics bulletin, Aidan has 20 years of reporting in detail on the global generic, biosimilar, value-added and OTC medicines industries.
With over 20 years of experience of reporting on the global pharmaceutical industry, Aidan focuses in his role as editor of Generics bulletin particularly on commercial, regulatory and legal issues affecting the generic, biosimilar, value-added and OTC medicines industries. This includes in-depth analyses of corporate strategy, legislative changes, legal precedents and product perspectives. He regularly interviews leading industry executives and moderates prestigious events. Aidan also oversees the Global Generics & Biosimilars Awards. Aidan speaks fluent German and has a particular affection for maps.

Analyst Articles

Articles by Aidan

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    California Plans To Create Own Generics Label

    California’s 2020-2021 fiscal budget includes plans to work with manufacturers to establish the state’s own generics label. But industry is sceptical that the initiative will deliver the savings that the US state hopes for.

    Topic Legislation policy-and-regulation

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Global Industry Hails Bioequivalence Progress

    For the first time, a working group within the International Council for Harmonization has started work on a regulatory topic specifically tailored to the global generics and biosimilars industry.

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Ophthalmics Are Next Frontier For Teligent

    US niche generics player Teligent intends to use its expertise in topical and injectable drugs manufacturing to push into the North American ophthalmics sector.